MSB

3.21%

$1.13 mesoblast limited

If the FDA grants a BLA on the weak evidence MSB has provided...

First 10055 Last

Share
Profile

Follow
col69

15,643 Posts.

5711

01/07/24

14:37

Post #: 74550033
Share

Originally posted by JB1975 ↑

End of the quarter no?

Should be an announcement about a BLA resubmission then, no?

I'm assuming no announcement is no resubmission yet as previously they have been announced when they've happened - but also previously they've been rescheduled later as well.

I read some links around one of LearningEachDays posts that gave me some background on a case within the FDA where one of the higher-ups Janet Woodcroft or Woodford or something overruled the principal investigators and an ODAC panel to grant a approval for a product in muscular dytrophy I think.

Only way I see the FDA saying what MSB alleges they've said especially as Silviu is reported to have said is if the FDA has similarly had internal over-ruling of scientists like Matt Klinker.

I think MSB is in a bubble (share price wise) and Cynata is (irrationally) bubbling along with it. If the FDA grants a BLA on the weak evidence MSB has provided I think it will harm the field (cell medicines) and the FDA will have a made a mess - succumbing to politicking and patient advocacy groups (perhaps they really have swayed Peter Marks - but they shouldn't have been able to on - not on the evidence MSB has put up).

MSB should have done an adult trial as the FDA were previously, sensibly, suggesting if not stating they should. I don't know if Peter Marks or others have the FDA have folded - its possible - but I hope not.

I do want MSB to get a BLA when they deserve to get it - but not before. If they get it before and without deserving it it will make for very bad policy and everyone coming afterwards will have to work around very bad policy. Which will slow down the delivery of affordable cell medicines.

Shareholders might cheer about the moats they've erected around themselves and then discover they'll die ahead of the medicines that they might have lived to see had the moats not been there.

Expand

If the FDA grants a BLA on the weak evidence MSB has provided

ROFL .... So you've seen the entire Remestemcel-L BLA resubmission document have you ? .... I mean no other HC posters have ?

Some of the comments you make that are stated/implied as facts are totally laughable just like the one above ... enough said

MSB Price at posting: 97.0¢ Sentiment: Buy Disclosure: Held
17 Upvote

1 Great analysis

Reply

Top Stories

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 1,016 more messages in this thread...

First 10055 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.13		Change 0.035(3.21%)		Mkt cap ! $1.284B

Open	High	Low	Value	Volume
$1.09	$1.13	$1.07	$3.910M	3.535M

Buyers (Bids)

No.	Vol.	Price($)
2	27197	$1.11

Sellers (Offers)

Price($)	Vol.	No.
$1.13	43578	3

View Market Depth

No.	Vol.	Price($)
4	31763	1.100
2	33264	1.090
2	18897	1.085
2	18926	1.080
1	18000	1.075

Price($)	Vol.	No.
1.130	23400	3
1.135	1090	1
1.140	65000	4
1.145	64500	3
1.150	92314	9

Last trade - 16.10pm 27/09/2024 (20 minute delay)

MSB (ASX) Chart

If the FDA grants a BLA on the weak evidence MSB has provided...

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACCC seeks Olam divestments before it can buy Namoi Cotton

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

If the FDA grants a BLA on the weak evidence MSB has provided...

Top Stories

KalGold rolls out detailed aeromagnetic survey across Pinjin project

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACCC seeks Olam divestments before it can buy Namoi Cotton

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News